1
|
Zhou YH, Li SX, Li L, Deng CM, Shen JJ, Wang DX, Chen XZ, Xu LL. Effect of Remimazolam Supplementation on Propofol Requirements During Hysteroscopy: A Double-Blind, Dose-Response Study. Anesth Analg 2024:00000539-990000000-00771. [PMID: 38412109 DOI: 10.1213/ane.0000000000006921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
BACKGROUND Propofol is commonly used for procedural sedation but may increase side effects in a dose-dependent manner. Remimazolam, an ultrashort-acting benzodiazepine, has been approved for procedural sedation but may delay awakening. This study tested the hypothesis that remimazolam as a supplement reduces effect-site propofol concentration (Ceprop) required to suppress response to cervical dilation in patients undergoing hysteroscopy. METHODS One hundred and fifty patients who were scheduled for hysteroscopy were randomized to receive 0, 0.05, 0.1, 0.15, or 0.2 mg·kg-1 intravenous remimazolam, followed by a bolus of sufentanil 0.15 μg⋅kg-1, and a target-controlled propofol infusion. The initial target Ceprop was 3.5 μg·mL-1 and was increased or decreased in subsequent patients by steps of 0.5 μg·mL-1 according to whether there was loss of response to cervical dilation in the previous patient. We used up-down sequential analysis to determine values of Ceprop that suppressed response to cervical dilation in 50% of patients (EC50). RESULTS The EC50 of propofol for suppressing response to cervical dilation was lower in patients given 0.1 mg·kg-1 (2.08 [95% confidence interval, CI, 1.88-2.28] μg·mL-1), 0.15 mg⋅kg-1 (1.83 [1.56-2.10] μg·mL-1), and 0.2 mg⋅kg-1 (1.43 [1.27-1.58] μg·mL-1) remimazolam than those given 0 mg⋅kg-1 (3.67 [3.49-3.86] μg·mL-1) or 0.05 mg⋅kg-1 (3.47 [3.28-3.67] μg·mL-1) remimazolam (all were P < .005). Remimazolam at doses of 0.1, 0.15, and 0.2 mg·kg-1 decreased EC50 of propofol by 43.3% (95% CI, 41.3%-45.5%), 50.3% (48.0%-52.8%), and 61.2% (58.7%-63.8%), respectively, from baseline (remimazolam 0 mg⋅kg-1). Propofol consumption was lower in patients given 0.1 mg⋅kg-1 (4.15 [3.51-5.44] mg·kg-1), 0.15 mg⋅kg-1 (3.54 [3.16-4.46] mg·kg-1), and 0.2 mg⋅kg-1 (2.74 [1.73-4.01] mg·kg-1) remimazolam than those given 0 mg⋅kg-1 (6.09 [4.99-7.35] mg·kg-1) remimazolam (all were P < .005). Time to anesthesia emergence did not differ significantly among the 5 groups. CONCLUSIONS For women undergoing hysteroscopic procedures, remimazolam at doses from 0.1 to 0.2 mg·kg-1 reduced the EC50 of propofol inhibiting response to cervical dilation and the total propofol requirement. Whether the combination could improve perioperative outcomes deserves further investigation.
Collapse
Affiliation(s)
- Yan-Hong Zhou
- From the Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
| | - Shu-Xi Li
- From the Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
| | - Lin Li
- From the Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
- Department of Anesthesia, Haiyan People's Hospital, Jiaxing, Zhejiang Province, China
| | - Chun-Mei Deng
- Department of Anesthesia, Peking University First Hospital, Beijing, China
| | - Jian-Jun Shen
- Department of Anesthesia, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
| | - Dong-Xin Wang
- Department of Anesthesia, Peking University First Hospital, Beijing, China
| | - Xin-Zhong Chen
- From the Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
| | - Li-Li Xu
- From the Department of Anesthesia, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China
| |
Collapse
|
3
|
Inácio QAS, Troncon JK, Valério FP, Herren H, Nogueira AA, Neto OBP, Silva JCRE. Misoprostol Administration Before Hysteroscopy Procedures - A Retrospective Analysis. REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA : REVISTA DA FEDERACAO BRASILEIRA DAS SOCIEDADES DE GINECOLOGIA E OBSTETRICIA 2022; 44:1102-1109. [PMID: 36037813 PMCID: PMC9800141 DOI: 10.1055/s-0042-1755462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
OBJECTIVE To evaluate the use of misoprostol prior to hysteroscopy procedures regarding technical ease, the presence of side effects, and the occurrence of complications. METHODS This is a retrospective, observational, analytical, case-control study, with the review of medical records of 266 patients followed-up at the Gynecological Videoendoscopy Sector of the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto of the Universidade de São Paulo (HCFMRP - USP, in the Portuguese acronym) from 2014 to 2019, comparing 133 patients who used the drug before the procedure with 133 patients who did not. RESULTS The occurrence of postmenopausal uterine bleeding was the main indication for hysteroscopy and revealed a statistical difference between groups (p < 0.001), being present in 93.23% of the patients in the study group and in 69.7% of the patients in the control group.: Only 2 patients (1.5%) in the study group reported adverse effects. Although no statistical differences were observed regarding the occurrence of complications during the procedure (p = 0.0662), a higher total number of complications was noted in the group that used misoprostol (n = 7; 5.26%) compared with the group that did not use the drug (n = 1; 0.75%), a fact that is clinically relevant. When evaluating the ease of the technique (measured by the complete performance of all steps of the hysteroscopy procedure), it was verified that although there was no difference between groups (p = 0.0586), the control group had more than twice as many incompletely performed procedures (n = 17) when compared with the group that used misoprostol previously (n = 8), which is also clinically relevant. CONCLUSION The use of misoprostol prior to hysteroscopy in our service indicated that the drug can facilitate the performance of the procedure, but not without side effects and presenting higher complication rates.
Collapse
Affiliation(s)
- Quênya Antunes Silveira Inácio
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Júlia Kefalás Troncon
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Fernando Passador Valério
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Helmer Herren
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Antônio Alberto Nogueira
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Omero Benedicto Poli Neto
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil
| | - Júlio César Rosa e Silva
- Departamento de Ginecologia e Obstetrícia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil,Address for correspondence Júlio César Rosa e Silva, MD, PhD Av. Bandeirantes3900, 14049-900, Ribeirão Preto, SPBrazil
| |
Collapse
|
5
|
Rund NMA, El Shenoufy H, Islam BA, El Husseiny T, Nassar SA, Mohsen RA, Alaa D, Gad Allah SH, Bakry A, Refaat R, Gehad MA, Kotb MMM, Osman OM, Ashour ASA, Ali AS, Taher A, Kholaif K, Hashem AT, Elsallamy AAH, Nour DA, Dahab S, Talaat B, Almohammady M. Determining the Optimal Time Interval between Vaginal Dinoprostone Administration and Diagnostic Office Hysteroscopy in Nulliparous Women: A Randomized, Double-blind Trial. J Minim Invasive Gynecol 2021; 29:85-93. [PMID: 34217851 DOI: 10.1016/j.jmig.2021.06.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 05/11/2021] [Accepted: 06/24/2021] [Indexed: 02/01/2023]
Abstract
STUDY OBJECTIVE To determine the optimal timing of vaginal dinoprostone administration before office hysteroscopy (OH) in nulliparous women. DESIGN Randomized, double-blind trial. SETTING Tertiary referral hospital. PATIENTS A total of 180 nulliparous women undergoing diagnostic OH. INTERVENTIONS We randomly allocated the women to long-interval or short-interval dinoprostone groups: three mg dinoprostone was administered vaginally 12 hours before OH in the long-interval group and 3 hours before OH in the short-interval group. MEASUREMENTS AND MAIN RESULTS The primary outcome was pain during OH measured using a 100-mm visual analog scale (0 = no pain; 100 = worst pain imaginable). The secondary outcomes were ease of hysteroscope passage, patient satisfaction score, and drug-related adverse effects. The patients in the long-interval dinoprostone group had lower pain scores during OH (p <.001). Contrarily, pain scores 30 minutes after the procedure were similar in both groups (p = .1). The patient satisfaction score was higher and clinicians found hysteroscope passage through the cervical canal easier and quicker in the long-interval dinoprostone group than in the short-interval group (p <.001, p = .003, and p <.001, respectively). Side effects were comparable in both study groups. CONCLUSION Vaginal dinoprostone administered 12 hours before OH was more effective than that administered 3 hours before OH in reducing pain during OH in nulliparous women, with easier hysteroscope insertion, shorter procedure duration, and higher patient satisfaction score.
Collapse
Affiliation(s)
- Nansy Mohamed Ali Rund
- Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University (Drs. Rund, Islam, and Nassar), Cairo
| | - Hossam El Shenoufy
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Bassem Aly Islam
- Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University (Drs. Rund, Islam, and Nassar), Cairo
| | - Tarek El Husseiny
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Salma Ashraf Nassar
- Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University (Drs. Rund, Islam, and Nassar), Cairo
| | - Reham A Mohsen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Doaa Alaa
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Sherine H Gad Allah
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Ahmed Bakry
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Rania Refaat
- Department of Obstetrics and Gynecology, Faculty of Medicine, Misr University for Science and Technology, 6th October City, Giza (Drs. Refaat and Elsallamy)
| | - Mahmoud Ahmed Gehad
- Department of Obstetrics and Gynecology, Faculty of Medicine, Benha University, Benha (Drs. Gehad and Talaat), Egypt
| | - Mohamed Mahmoud Mohamed Kotb
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Omneya M Osman
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Ahmed S A Ashour
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Ahmed Said Ali
- Faculty of Medicine, Al-Azhar University (Dr. Ali), Cairo.
| | - Ayman Taher
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Khaled Kholaif
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Ahmed T Hashem
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Ayman Aly Hamed Elsallamy
- Department of Obstetrics and Gynecology, Faculty of Medicine, Misr University for Science and Technology, 6th October City, Giza (Drs. Refaat and Elsallamy)
| | - Dalia Adel Nour
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Sherif Dahab
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| | - Bassem Talaat
- Department of Obstetrics and Gynecology, Faculty of Medicine, Benha University, Benha (Drs. Gehad and Talaat), Egypt; Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, (Dr. Talaat) Egypt
| | - Maged Almohammady
- Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University (Drs. El Shenoufy, El Husseiny, Mohsen, Alaa, Gad Allah, Bakry, Kotb, Osman, Ashour, Taher, Kholaif, Hashem, Nour, Dahab, and Almohammady), Cairo
| |
Collapse
|